Establishment of digital health demonstration and academic cooperation system...MOU with Daewoong Pharmaceutical Co., Ltd. and Korea General Health Management Association
Aug 05, 2025
|
Officials from both sides attended the agreement ceremony held at Daewoong Pharmaceutical's headquarters on the 5th, including Lee Chang-jae, CEO of Daewoong Pharmaceutical, Dong Seok-ho, chairman of the Korea General Health Management Association, and Chairman Cho Jung-yeon.
Through this agreement, Daewoong Pharmaceutical and Daejonggun will jointly promote ▲ academic activities and research promotion ▲ advisory and demonstration projects related to digital healthcare diagnostic devices ▲ medical service and ESG linkage activities ▲ health care cooperation projects agreed by the two organizations.
Daewoong Pharmaceutical plans to collaborate with Daejonggun to expand academic events related to digital health-based health checkups and actively invest in new digital health technologies. Daejonggun plans to secure medical reliability through clinical advice and product demonstration of digital health technology, strengthen its academic foundation, and promote systematic product verification.
Daewoong Pharmaceutical has previously signed an agreement with the Korea Health Examination Institution Council to supply digital diagnostic devices to parliamentary-level institutions, and has focused on improving field-oriented detailed examinations and improving access to medical care. With this agreement with Daejong, the products under consideration can be demonstrated (PoC) at the actual examination site, and the effectiveness and reliability can be verified based on clinical advice and data. In particular, collaboration with Daejonggun, which includes major examination institutions such as Seoul National University Hospital Gangnam Center, Seoul Asan Hospital, and the Korea Health Management Association, is expected to be an important basis for securing the academic feasibility of digital health technology.
Furthermore, Daewoong Pharmaceutical plans to lead innovation in the health management paradigm and make practical and sustainable contributions to public health promotion by developing and expanding the entire cycle of 'prevention-early diagnosis-treatment-post management' based on digital health with the society. Daewoong Pharmaceutical is expanding its latest digital health precision diagnosis products such as MobiCare, Cart BP, Libre, Etia, and Whiskey to the health examination area beyond the existing medical field.
Meanwhile, since its foundation in 1986 to contribute to the promotion and management of national health, more than 100 excellent hospitals and centers nationwide have joined to promote national health through early diagnosis and prevention of diseases. Recently, with the development of the digital health care industry, the latest diagnostic tests have been actively introduced, leading precision medical care in the field of examination.
Dong Seok-ho, Chairman of the Korean Society for Comprehensive Health Management, said "We expect that the professionalism of the society and Daewoong Pharmaceutical's healthcare technology will meet to create various demonstration and research results."Future health checkups will increase screening accuracy by combining artificial intelligence (AI), dielectric, and digital healthcare technologies, and develop into an integrated form that encompasses disease prediction and early diagnosis as well as health care, and this cooperation will be an exemplary model that considers not only medical values but also social contributions."
Lee Chang-jae, CEO of Daewoong Pharmaceutical, said "Through this agreement, we plan to further develop and expand the entire health care cycle from prevention, early diagnosis, treatment, and follow-up management with the Korean Society for Comprehensive Health Management based on Daewoong Pharmaceutical's various digital health technologies."
This article was translated by Naver AI translator.
